Biologic drugs play a key role in the US healthcare market, as they are often the standard of care for treating complex diseases, many of which require long-term treatment. With the FDA’s approval of biosimilars of several important biologic treatments, and with a significant pipeline of biosimilars still in development, it is expected that many biosimilars will be introduced to the US market in the next several years.
Biologic drugs play a key role in the US healthcare market, as they are often the standard of care for treating complex diseases, many of which require long-term treatment. With the FDA’s approval of biosimilars of several important biologic treatments, and with a significant pipeline of biosimilars still in development, it is expected that many biosimilars will be introduced to the US market in the next several years.
As new biosimilars are approved, and as patients, healthcare providers, and payers benefit from the additional therapeutic options they provide, biosimilars will play an increasingly important role, according to a recent assessment published by the Healthcare Distribution Alliance (HAD) Research Foundation. The report, “The State of the US Biosimilar Market,” draws on a series of interviews with senior stakeholders at specialty distributors and pharmaceutical manufacturers, as well as on secondary research, to describe the current state of the market and to provide perspective on the unique challenges of bringing biosimilars to marketplace.
Since the FDA’s first biosimilar approval in January 2015—Sandoz’s Zarxio, a biosimilar of Amgen’s reference filgrastim Neupogen—the FDA has approved 8 additional biosimilars. Three have launched: Zarxio, Inflectra, and Renflexis (the latter 2 both biosimilars of Remicade).
The analysis discusses the marketing of these 3 biosimilars, the highlights of which include:
The Biosimilar Pipeline
As of March 2017, there were 66 biosimilar development programs in the FDA’s Biosimilar Drug Development Program. By 2019, 6 of the top 10 US biologic drugs will lose patent exclusivity—including Avastin, Humira, Neulasta, Remicade, and Rituxan, which have a combined market value of $32.2 billion, making them and other biologics attractive targets for biosimilar development.
Challenges
There are unique challenges facing biosimilar products that are approved and launched, according to interviews with senior executives at pharmaceutical manufacturers and distributors. The US biosimilar market has been slower to develop than that of many other developed countries because of a slower pace of a supporting regulatory framework. “Manufacturer, distributor, and payer strategies for managing biosimilars are evolving while providers and patients slowly begin to understand what biosimilars are, and how they fit into their healthcare options,” the analysis states. Challenges include the following:
Conclusion
The pace of biosimilar adoption in the United States is dependent upon the actions of many different industry stakeholders, including payers, providers, and manufacturers, but the analysis predicts that biosimilars in the pipeline will be launched more regularly in the coming years as the biosimilar drugs now in development are approved. Payers are likely to encourage a transition to biosimilars, as they expect them to provide cost savings over branded biologics. As biosimilar pricing evolves, and as additional biosimilars are launched for the same reference drugs, prices may fall further, resulting in savings to patients and the healthcare system as a whole. However, pricing at launch and corresponding savings to the healthcare system will continue to depend on the price of reference drugs, and this price often increases in the years leading up to the loss of exclusivity.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.